Causal Inference for Definitive Clinical End Points in a Randomized Clinical Trial With Intervening Nonrandomized Treatments

被引：6

作者：

Korn, Edward L. ^{[1
]}

Freidlin, Boris ^{[1
]}

机构：

[1] NCI, Bethesda, MD 20892 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 24期

关键词：

RENAL-CELL CARCINOMA; PHASE-III TRIAL; CANCER; EFFICACY;

D O I：

10.1200/JCO.2010.30.0442

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3800 / 3802

页数：4

共 11 条

[1] Estimating a treatment effect in survival studies in which patients switch treatment [J].

Branson, M ;

Whitehead, J .

STATISTICS IN MEDICINE, 2002, 21 (17) :2449-2463

[2] Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Staehler, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Anderson, Sibyl ;

Hofilena, Gloria ;

Shan, Minghua ;

Pena, Carol ;

Lathia, Chetan ;

Bukowski, Ronald M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3312-3318

[3] Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study [J].

Kaufman, Bella ;

Mackey, John R. ;

Clemens, Michael R. ;

Bapsy, Poonamalle P. ;

Vaid, Ashok ;

Wardley, Andrew ;

Tjulandin, Sergei ;

Jahn, Michaela ;

Lehle, Michaela ;

Feyereislova, Andrea ;

Revil, Cedric ;

Jones, Alison .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5529-5537

[4] Causal inference through potential outcomes and principal stratification: Application to studies with "censoring" due to death - Comments and rejoiners [J].

Korn, Edward L. ;

Rosenbaum, Paul R. ;

Fienberg, Stephen E. ;

Rubin, Donald B. .

STATISTICAL SCIENCE, 2006, 21 (03) :310-321

[5]

Korn EL, 1998, STAT SCI, V13, P209

[6] Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study [J].

London, Wendy B. ;

Frantz, Christopher N. ;

Campbell, Laura A. ;

Seeger, Robert C. ;

Brumback, Babette A. ;

Cohn, Susan L. ;

Matthay, Katherine K. ;

Castleberry, Robert P. ;

Diller, Lisa .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (24) :3808-3815

[7] Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial [J].

Motzer, Robert J. ;

Escudier, Bernard ;

Oudard, Stephane ;

Hutson, Thomas E. ;

Porta, Camillo ;

Bracarda, Sergio ;

Gruenwald, Viktor ;

Thompson, John A. ;

Figlin, Robert A. ;

Hollaender, Norbert ;

Urbanowitz, Gladys ;

Berg, William J. ;

Kay, Andrea ;

Lebwohl, David ;

Ravaud, Alain .

LANCET, 2008, 372 (9637) :449-456

[8]

National Institute for Health and Clinical Excellence, 179 NAT I HLTH CLIN

[9]

ROBBINS JM, 1991, COMMUN STAT-THEOR M, V20, P2609

[10] EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer [J].

Sobrero, Alberto F. ;

Maurel, Joan ;

Fehrenbacher, Louis ;

Scheithauer, Werner ;

Abubakr, Yousif A. ;

Lutz, Manfred P. ;

Vega-Villegas, M. Eugenia ;

Eng, Cathy ;

Steinhauer, Ernst U. ;

Prausova, Jana ;

Lenz, Heinz-Josef ;

Borg, Christophe ;

Middleton, Gary ;

Kroening, Hendrik ;

Luppi, Gabriele ;

Kisker, Oliver ;

Zubel, Angela ;

Langer, Christiane ;

Kopit, Justin ;

Burris, Howard A., III .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) :2311-2319

← 1 2 →